請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48794完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 鄧述諄 | |
| dc.contributor.author | Cheng-Hui Tsai | en |
| dc.contributor.author | 蔡振輝 | zh_TW |
| dc.date.accessioned | 2021-06-15T11:09:27Z | - |
| dc.date.available | 2020-03-01 | |
| dc.date.copyright | 2017-03-01 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-10-24 | |
| dc.identifier.citation | 1. Felsenfeld G, Emerson BM, Jackson PD, Lewis CD, Nickol JM. Chromatin structure near transcriptionally active genes. Prog Clin Biol Res. 1986;218:63-74.
2. Felsenfeld G, McGhee JD. Structure of the 30 nm chromatin fiber. Cell. 1986;44:375-7. 3. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41-5. 4. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell. 2007;128:707-19. 5. Valk-Lingbeek ME, Bruggeman SWM, van Lohuizen M. Stem Cells and Cancer: The Polycomb Connection. Cell. 2004;118:409-18. 6. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatology Research. 2007;37:974-83. 7. Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One. 2008;3:e2037. 8. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823-33. 9. Liu L, Kimball S, Liu H, Holowatyj A, Yang ZQ. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget. 2015;6:2466-82. 10. Marmorstein R. Structure of SET domain proteins: a new twist on histone methylation. Trends in biochemical sciences. 2003;28:59-62. 11. Takahashi Y-H, Shilatifard A. Structural basis for H3K4 trimethylation by yeast Set1/COMPASS. Advances in Enzyme Regulation. 2010;50:104-10. 12. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001;20:5695-707. 13. Strahl BD, Grant PA, Briggs SD, Sun Z-W, Bone JR, Caldwell JA, et al. Set2 Is a Nucleosomal Histone H3-Selective Methyltransferase That Mediates Transcriptional Repression. Molecular and Cellular Biology. 2002;22:1298-306. 14. Wang X, Yeh S, Wu G, Hsu C-L, Wang L, Chiang T, et al. Identification and Characterization of a Novel Androgen Receptor Coregulator ARA267-alpha in Prostate Cancer Cells. J Biol Chem. 2001;276:40417-23. 15. Brown MA, Sims RJ, 3rd, Gottlieb PD, Tucker PW. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Molecular cancer. 2006;5:26. 16. Spellmon N, Holcomb J, Trescott L, Sirinupong N, Yang Z. Structure and function of SET and MYND domain-containing proteins. International journal of molecular sciences. 2015;16:1406-28. 17. Tan X, Rotllant J, Li H, De Deyne P, Du SJ. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc Natl Acad Sci U S A. 2006;103:2713-8. 18. Keogh M-C, Kurdistani SK, Morris SA, Ahn SH, Podolny V, Collins SR, et al. Cotranscriptional Set2 Methylation of Histone H3 Lysine 36 Recruits a Repressive Rpd3 Complex. Cell. 2005;123:593-605. 19. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004;6:731-40. 20. Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos AF, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics : official journal of the DNA Methylation Society. 2012;7:340-3. 21. Foreman KW, Brown M, Park F, Emtage S, Harriss J, Das C, et al. Structural and functional profiling of the human histone methyltransferase SMYD3. PLoS One. 2011;6:e22290. 22. Stender JD, Pascual G, Liu W, Kaikkonen MU, Do K, Spann NJ, et al. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Molecular cell. 2012;48:28-38. 23. Vieira FQ, Costa-Pinheiro P, Almeida-Rios D, Graca I, Monteiro-Reis S, Simoes-Sousa S, et al. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3. Oncotarget. 2015;6:13644-57. 24. Frank B, Hemminki K, Wappenschmidt B, Klaes R, Meindl A, Schmutzler RK, et al. Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer. Int J Cancer. 2006;118:2917-8. 25. Sarris ME, Moulos P, Haroniti A, Giakountis A, Talianidis I. Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development. Cancer Cell. 2016;29:354-66. 26. Liu C, Fang X, Ge Z, Jalink M, Kyo S, Bjorkholm M, et al. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res. 2007;67:2626-31. 27. Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014;510:283-7. 28. Mazur PK, Gozani O, Sage J, Reynoird N. Novel insights into the oncogenic function of the SMYD3 lysine methyltransferase. Transl Cancer Res. 2016;5:330-3. 29. Valdes-Mora F, Song JZ, Statham AL, Strbenac D, Robinson MD, Nair SS, et al. Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer. Genome research. 2012;22:307-21. 30. Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA, et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Molecular systems biology. 2008;4:188. 31. Yang HD, Kim PJ, Eun JW, Shen Q, Kim HS, Shin WC, et al. Oncogenic potential of histone-variant H2A.Z.1 and its regulatory role in cell cycle and epithelial-mesenchymal transition in liver cancer. Oncotarget. 2016;7:11412-23. 32. Kim K, Punj V, Choi J, Heo K, Kim JM, Laird PW, et al. Gene dysregulation by histone variant H2A.Z in bladder cancer. Epigenetics & chromatin. 2013;6:34. 33. Horikoshi N, Sato K, Shimada K, Arimura Y, Osakabe A, Tachiwana H, et al. Structural polymorphism in the L1 loop regions of human H2A.Z.1 and H2A.Z.2. Acta crystallographica Section D, Biological crystallography. 2013;69:2431-9. 34. Dryhurst D, Ishibashi T, Rose KL, Eirin-Lopez JM, McDonald D, Silva-Moreno B, et al. Characterization of the histone H2A.Z-1 and H2A.Z-2 isoforms in vertebrates. BMC Biol. 2009;7:86. 35. Vardabasso C, Gaspar-Maia A, Hasson D, Punzeler S, Valle-Garcia D, Straub T, et al. Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. Mol Cell. 2015;59:75-88. 36. Ruhl DD, Jin J, Cai Y, Swanson S, Florens L, Washburn MP, et al. Purification of a human SRCAP complex that remodels chromatin by incorporating the histone variant H2A.Z into nucleosomes. Biochemistry. 2006;45:5671-7. 37. Liang X, Shan S, Pan L, Zhao J, Ranjan A, Wang F, et al. Structural basis of H2A.Z recognition by SRCAP chromatin-remodeling subunit YL1. Nat Struct Mol Biol. 2016;23:317-23. 38. Obri A, Ouararhni K, Papin C, Diebold ML, Padmanabhan K, Marek M, et al. ANP32E is a histone chaperone that removes H2A.Z from chromatin. Nature. 2014;505:648-53. 39. Latrick CM, Marek M, Ouararhni K, Papin C, Stoll I, Ignatyeva M, et al. Molecular basis and specificity of H2A.Z-H2B recognition and deposition by the histone chaperone YL1. Nat Struct Mol Biol. 2016;23:309-16. 40. Dryhurst D, McMullen B, Fazli L, Rennie PS, Ausio J. Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression. Cancer Lett. 2012;315:38-47. 41. Draker R, Ng MK, Sarcinella E, Ignatchenko V, Kislinger T, Cheung P. A combination of H2A.Z and H4 acetylation recruits Brd2 to chromatin during transcriptional activation. PLoS Genet. 2012;8:e1003047. 42. Singh RK, Kabbaj M-HM, Paik J, Gunjan A. Histone levels are regulated by phosphorylation and ubiquitylation-dependent proteolysis. Nat Cell Biol. 2009;11:925-33. 43. Suto RK, Clarkson MJ, Tremethick DJ, Luger K. Crystal structure of a nucleosome core particle containing the variant histone H2A.Z. Nature structural biology. 2000;7:1121-4. 44. Wang AY, Aristizabal MJ, Ryan C, Krogan NJ, Kobor MS. Key functional regions in the histone variant H2A.Z C-terminal docking domain. Mol Cell Biol. 2011;31:3871-84. 45. Jensen K, Santisteban MS, Urekar C, Smith MM. Histone H2A.Z acid patch residues required for deposition and function. Molecular genetics and genomics : MGG. 2011;285:287-96. 46. Subramanian V, Mazumder A, Surface LE, Butty VL, Fields PA, Alwan A, et al. H2A.Z acidic patch couples chromatin dynamics to regulation of gene expression programs during ESC differentiation. PLoS genetics. 2013;9:e1003725. 47. Krogan NJ, Baetz K, Keogh MC, Datta N, Sawa C, Kwok TC, et al. Regulation of chromosome stability by the histone H2A variant Htz1, the Swr1 chromatin remodeling complex, and the histone acetyltransferase NuA4. Proc Natl Acad Sci U S A. 2004;101:13513-8. 48. Wong MM, Cox LK, Chrivia JC. The chromatin remodeling protein, SRCAP, is critical for deposition of the histone variant H2A.Z at promoters. The Journal of biological chemistry. 2007;282:26132-9. 49. Auger A, Galarneau L, Altaf M, Nourani A, Doyon Y, Utley RT, et al. Eaf1 is the platform for NuA4 molecular assembly that evolutionarily links chromatin acetylation to ATP-dependent exchange of histone H2A variants. Mol Cell Biol. 2008;28:2257-70. 50. Mao Z, Pan L, Wang W, Sun J, Shan S, Dong Q, et al. Anp32e, a higher eukaryotic histone chaperone directs preferential recognition for H2A.Z. Cell research. 2014;24:389-99. 51. Hyland EM, Molina H, Poorey K, Jie C, Xie Z, Dai J, et al. An evolutionarily ‘young’ lysine residue in histone H3 attenuates transcriptional output in Saccharomyces cerevisiae. Genes & Development. 2011;25:1306-19. 52. Jensen K, Santisteban MS, Urekar C, Smith MM. Histone H2A.Z acid patch residues required for deposition and function. Mol Genet Genomics. 2011;285:287-96. 53. Wang AY, Aristizabal MJ, Ryan C, Krogan NJ, Kobor MS. Key Functional Regions in the Histone Variant H2A.Z C-Terminal Docking Domain. Mol Cell Biol. 2011;31:3871-84. 54. Subramanian V, Mazumder A, Surface LE, Butty VL, Fields PA, Alwan A, et al. H2A.Z Acidic Patch Couples Chromatin Dynamics to Regulation of Gene Expression Programs during ESC Differentiation. Plos Genet. 2013;9. 55. Park YJ, Chodaparambil JV, Bao Y, McBryant SJ, Luger K. Nucleosome assembly protein 1 exchanges histone H2A-H2B dimers and assists nucleosome sliding. The Journal of biological chemistry. 2005;280:1817-25. 56. Hoch DA, Stratton JJ, Gloss LM. Protein-protein Forster resonance energy transfer analysis of nucleosome core particles containing H2A and H2A.Z. Journal of molecular biology. 2007;371:971-88. 57. Ren TN, Wang JS, He YM, Xu CL, Wang SZ, Xi T. Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells. Med Oncol. 2011;28 Suppl 1:S91-8. 58. Zlatanova J, Thakar A. H2A.Z: view from the top. Structure. 2008;16:166-79. 59. Svotelis A, Gevry N, Grondin G, Gaudreau L. H2A.Z overexpression promotes cellular proliferation of breast cancer cells. Cell Cycle. 2010;9:364-70. 60. Kim H, Heo K, Kim JH, Kim K, Choi J, An W. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. The Journal of biological chemistry. 2009;284:19867-77. 61. Nagata DE, Ting HA, Cavassani KA, Schaller MA, Mukherjee S, Ptaschinski C, et al. Epigenetic control of Foxp3 by SMYD3 H3K4 histone methyltransferase controls iTreg development and regulates pathogenic T-cell responses during pulmonary viral infection. Mucosal Immunol. 2015;8:1131-43. 62. Holm C, Ora I, Brunhoff C, Anagnostaki L, Landberg G, Persson JL. Cyclin A1 expression and associations with disease characteristics in childhood acute lymphoblastic leukemia. Leukemia research. 2006;30:254-61. 63. Ji P, Agrawal S, Diederichs S, Baumer N, Becker A, Cauvet T, et al. Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene. 2005;24:2739-44. 64. Hsia DA, Tepper CG, Pochampalli MR, Hsia EYC, Izumiya C, Huerta SB, et al. KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation. Proceedings of the National Academy of Sciences. 2010;107:9671-6. 65. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993;7:1559-71. 66. Dalvai M, Bellucci L, Fleury L, Lavigne AC, Moutahir F, Bystricky K. H2A.Z-dependent crosstalk between enhancer and promoter regulates cyclin D1 expression. Oncogene. 2013;32:4243-51. 67. Hu G, Cui K, Northrup D, Liu C, Wang C, Tang Q, et al. H2A.Z facilitates access of active and repressive complexes to chromatin in embryonic stem cell self-renewal and differentiation. Cell stem cell. 2013;12:180-92. 68. Bonisch C, Schneider K, Punzeler S, Wiedemann SM, Bielmeier C, Bocola M, et al. H2A.Z.2.2 is an alternatively spliced histone H2A.Z variant that causes severe nucleosome destabilization. Nucleic acids research. 2012;40:5951-64. 69. Hashimoto H, Takami Y, Sonoda E, Iwasaki T, Iwano H, Tachibana M, et al. Histone H1 null vertebrate cells exhibit altered nucleosome architecture. Nucleic acids research. 2010;38:3533-45. 70. Pai CC, Deegan RS, Subramanian L, Gal C, Sarkar S, Blaikley EJ, et al. A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice. Nature communications. 2014;5:4091. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48794 | - |
| dc.description.abstract | 甲基酶SMYD3在一般細胞中幾乎偵測不到，然而在數種癌細胞中卻有著高度的表現。目前對於SMYD3和癌細胞惡化的關係與其機制沒有全然的了解。在此我發現了一個新的SMYD3的受質H2A.Z。實驗指出SMYD3可藉由在H2A.Z的第101個胺基酸(離胺酸)上甲基化來增加H2A.Z及含有H2A.Z的核小體的穩定度。H2A.Z藉由甲基化防止和其伴護蛋白ANP32E結合，避免自核小體中被移除，同時增加和組蛋白H3的結合能力。此外，藉由微陣列基因晶片表現分析指出cyclin A1受SMYD3和H2A.ZK101me2調控。SMYD3和H2A.ZK101me2共同坐落於cyclin A1的啟動子區，活化期其表現並促進細胞週期G1/S的進程。在動物實驗中，於H2A.ZK101點突變的細胞中額外表現了cyclin A1亦可以促使癌細胞生長成腫瘤的能力。綜合以上我的發現，推測SMYD3所引起的H2A.ZK101me2可促進cyclin A1的表現，並促進乳癌細胞的增生。 | zh_TW |
| dc.description.abstract | The methyltransferase SMYD3 is nearly undetectable in normal human tissues but highly expressed in several cancers. The underlying mechanism by which SMYD3 is associated with tumor malignancy is not completely understood. Here, we demonstrate that histone H2A.Z is a novel substrate of SMYD3. SMYD3-mediated dimethylation of H2A.Z at lysine 101 (H2A.ZK101me2) could increase the stability of H2A.Z and the H2A.Z-containing nucleosomes by preventing its binding to the removal chaperon ANP32E and facilitate H2A.Z interaction with histone H3. Moreover, using microarray analysis, cyclin A1 was identified and its expression was co-regulated by SMYD3 and H2A.ZK101me2. The co-localization of SMYD3 and H2A.ZK101me2 was found at the promoter of cyclin A1 to up-regulate the gene expression and to promote G1/S progression. Consistently, exogenous expression of cyclin A1 in cells containing H2A.ZK101 mutants rescued tumor formation in a mouse model. Together our findings suggest that SMYD3-mediated H2A.ZK101 dimethylation activates cyclin A1 expression and contributes to breast cancer cell proliferation. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T11:09:27Z (GMT). No. of bitstreams: 1 ntu-105-D97445002-1.pdf: 6696923 bytes, checksum: d04a1137482c3a35102f034b0a45020d (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
致謝 ii 中文摘要 iii Abstract iv Introduction 1 Results 5 Discussion 15 Materials and Methods 18 Figures and Figure Legends 28 Tables 45 References 50 Appendixes 58 | |
| dc.language.iso | en | |
| dc.subject | 甲基? | zh_TW |
| dc.subject | 組蛋白 | zh_TW |
| dc.subject | 細胞增生 | zh_TW |
| dc.subject | 乳癌細胞 | zh_TW |
| dc.subject | 細胞週期 | zh_TW |
| dc.subject | Histone H2A.Z | en |
| dc.subject | breast cancer | en |
| dc.subject | cyclin A1 | en |
| dc.subject | methyltransferase | en |
| dc.subject | SMYD3 | en |
| dc.title | SMYD3調控H2A.Z甲基化促進細胞周期與細胞增生 | zh_TW |
| dc.title | SMYD3-Mediated H2A.Z Methylation Promotes Cell Cycle and Cancer Proliferation | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 105-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 李明學,曾秀如,李財坤,阮麗蓉 | |
| dc.subject.keyword | 甲基?,組蛋白,乳癌細胞,細胞週期,細胞增生, | zh_TW |
| dc.subject.keyword | SMYD3,methyltransferase,Histone H2A.Z,cyclin A1,breast cancer, | en |
| dc.relation.page | 73 | |
| dc.identifier.doi | 10.6342/NTU201603704 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2016-10-24 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 未授權公開取用 | 6.54 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。